<DOC>
	<DOCNO>NCT01929577</DOCNO>
	<brief_summary>The purpose study determine relative bioavailability ASP015K fast condition single-dose administration test-tablet formulation reference-tablet formulation . This study also evaluate food effect bioavailability test formulation , evaluate safety tolerability single-dose administration test- reference-tablet formulation .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Between Two ASP015K Tablets Food Effect New Tablet Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Female subject must nonchildbearing potential ( i.e. , postmenopausal [ define least 1 year without menses prior screen ] , document surgically sterile status post hysterectomy [ least 1 month prior screen ] ) . Female subject must negative pregnancy test screen day 1 treatment period 1 . Female subject must donate ovum start screen throughout study period , 90 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start screen continue throughout study period 90 day final study drug administration . Male subject must donate sperm start screen throughout study period 90 day final study drug administration . Subject Body Mass Index ( BMI ) range 18.532.0 kg/m2 , inclusive , must weigh least 50 kg screening . Female subject pregnant within 6 month screen assessment breast feeding within 3 month screen . Subject know suspected hypersensitivity ASP015K , component formulation use . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior first clinic checkin . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's Wort ) 2 week prior study drug administration , exception hormone replacement therapy ( HRT ) , intermittent acetaminophen ( maximum 2 g/day ) . Subject smoke used tobaccocontaining product nicotine nicotinecontaining product past six month prior screen . Subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical substance abuse within past 2 year prior screen ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) prior day 1 treatment period 1 . Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic checkin day 1 treatment period 1 . Subject positive test hepatitis B surface antigen ( HBsAg ) , antihepatitis A virus ( HAV ) ( Immunoglobulin [ Ig ] M ) , antihepatitis C virus ( HCV ) , hepatitis B core antibody , antihuman immunodeficiency virus ( HIV ) type 1 type 2 screening . Subject positive tuberculosis ( TB ) skin test , Quantiferon Gold® test TSPOT® test screening . Subject receive vaccine within 60 day prior study drug administration . Subject absolute neutrophil count ( ANC ) &lt; 2000 cells/mm3 creatine phosphokinase ( CPK ) &gt; 1.5 x ULN screen day 1 treatment period 1 . Subject major gastrointestinal ( GI ) surgery medical condition , may inhibit absorption and/or metabolism study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>healthy subject</keyword>
</DOC>